Comment on: Jilkova, ZM; et al. "Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" Cancers 2019, 11, 1554

被引：0

作者：

Dunnigan, Anna ^{[1
]}

机构：

[1] UCL, Inst Clin Trials & Methodol, London WC1V 6LJ, England

来源：

CANCERS | 2020年 / 12卷 / 09期

关键词：

D O I：

10.3390/cancers12092670

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1

共 8 条

[1] Reply to Comment on "Jilkova, ZM; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" Cancers 2019, 11, 1554
Macek Jilkova, Zuzana
Aspord, Caroline
Decaens, Thomas
[J]. CANCERS, 2020, 12 (09)
[2] Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
Jilkova, Zuzana Macek
Aspord, Caroline
Decaens, Thomas
[J]. CANCERS, 2019, 11 (10)
[3] Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition
Sodji, Quaovi
Klein, Kandy
Sravan, Kavuri
Parikh, Jigarkumar
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[4] Comment on Chen et al. Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin. Biomolecules 2021, 11, 1373
Stransky, Nicolai
Huber, Stephan M.
[J]. BIOMOLECULES, 2022, 12 (04)
[5] Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer"
Sun, Jong-Mu
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : E56 - E57
[6] Re: Maud Rijnders, Astrid AM van der Veldt, Tahlita CM Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40
Gevaert, Thomas
Eckstein, Markus
Montironi, Rodolfo
Lopez-Beltran, Antonio
[J]. EUROPEAN UROLOGY, 2019, 75 (06) : E162 - E163
[7] Comment on the manuscript "Histological subtype is associated with PD-L1 expression and CD8 thorn T-cell infiltrates in triple-negative breast carcinoma" by Salisbury et al. (Ann Diagn Pathol 2022; 57: 151901, https://doi.org/10.1016/j.anndiagpath.2022.151901)
Vranic, Semir
[J]. ANNALS OF DIAGNOSTIC PATHOLOGY, 2022, 58
[8] Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid AM van der Veldt, Tahlita CM Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40
Rijnders, Maud
van der Veldt, Astrid A. M.
de Wit, Ronald
van Leenders, Geert J. L. H.
[J]. EUROPEAN UROLOGY, 2019, 75 (06) : E160 - E161

← 1 →